Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SLAS Establishes an Endowed Fellowship for Novel Drug Development Research at the University of California Los Angeles

Published: Friday, June 15, 2012
Last Updated: Thursday, June 14, 2012
Bookmark and Share
Fellowship supports novel and innovative cancer research initiatives

The Society for Laboratory Automation and Screening (SLAS) has established an Endowed Fellowship at the University of California Los Angeles (UCLA) to support novel and innovative cancer research initiatives that are aligned with the scientific focus of the Society.
 
Through the SLAS Endowment Fund, SLAS will support a new UCLA School of Dentistry research program based on the development of novel technologies that serve as vehicles for therapeutic molecular compounds.  The research team will perform algorithm-driven feedback analysis to identify optimal combinations of nanodiamond-drug complexes, analogous to screening, in order to realize compounds that are capable of simultaneously maximized efficacy and safety.  The UCLA team will be led by Professor Dean Ho, PhD (who begins his tenure with the UCLA School of Dentistry on July 1, 2012) in collaboration with Professor Cun-Yu Wang, DDS, PhD, who is the No-Hee Park Endowed Professor and Chair of Oral Biology and Medicine at the UCLA School of Dentistry, and a fellow of the American Association for the Advancement of Science who was recently honored with election to the Institute of Medicine of the National Academies.
 
“UCLA is deeply committed to working in partnership with SLAS to support this internationally-recognized innovation in novel drug development,” says No-Hee Park, DMD, PhD, Dean and Distinguished Professor of the UCLA School of Dentistry.  “Our school is very excited for the recruitment of Professor Dean Ho, a world class scholar.”  Dr. Wang adds, “This generous fellowship from SLAS will bring Dean and me together to address some important questions in cancer therapeutics and train a new generation of scientists.”
 
According to Professor Ho, “The project involves the screening for and development of novel therapeutic compounds for the co-suppression of inflammation and tumor growth using a multi-functional nanodiamond-drug complex.  Because it is believed that dual therapy against inflammation and cancer can mediate significantly enhanced treatment outcomes, the combinatorial screening for optimal drug combinations that are nanodiamond-modified to overcome chemoresistance may result in transformative advancements in the field.”
 
This SLAS award is the first to be made from the SLAS Endowment Fund. Originally established by the Society of Biomolecular Sciences (SBS) prior to its merger with the Association for Laboratory Automation (ALA) to form the Society for Laboratory Automation and Screening (SLAS), the fund’s purpose is to provide start-up funding for research projects with the potential to advance the disciplines, technologies, and skills involved in screening and molecular discovery, including support of graduate and undergraduate training in these areas.  An initial $100,000 commitment to UCLA will be reviewed and reconsidered after five years.
 
“The SLAS Endowment Fund is an important component of our organization,” says SLAS President Dave Dorsett.  “It broadens our reach and impact in the scientific community, and it speaks directly to our mission to provide forums for education and information exchange to encourage the study of, and improve the science and practice of, laboratory automation and screening.”
 
“SLAS is extremely proud to be associated with UCLA and this ambitious new research program,” Dorsett continues.  “A state-of-the-art cancer research facility is being established at the UCLA School of Dentistry Yip Center for Oral/Head & Neck Oncology Research to house this initiative.  In addition, UCLA is home to the Jane and Jerry Weintraub Center for Reconstructive Biotechnology, which provides an environment in which translational/clinical trial research can be accomplished.  These are highly unique facilities that promote multidisciplinary collaborations.”
 
“The laboratory science and technology embraced through this impressive initiative will be of great interest to current and future SLAS members,” says SLAS CEO Greg Dummer.  “Our entire scientific community will benefit from developments published in our scientific journals, at our annual conferences and on our website.  In the meantime, we welcome the opportunity to have a positive impact on the undergraduate, graduate and post-doctoral students who will have hands-on involvement in the project and hope that we’ll see them emerge as our Society’s next generation of scientific leaders.”
 
“As the SLAS Endowment Fund grows, SLAS looks forward to being able to support other meaningful new research initiatives across the U.S. and around the world,” says Dorsett.  An application process will be announced at a later date at SLAS.org.
 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!